<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17236" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adrenal Myelolipoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Maria R.</given-names>
          </name>
          <aff>Tulane Hospital , Louisiana</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zulfiqar</surname>
            <given-names>Hassam</given-names>
          </name>
          <aff>Hamad Medical Corporation, Doha, Qatar</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garla</surname>
            <given-names>Vishnu V.</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vishnu Garla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17236.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Adrenal myelolipomas represent benign adrenal neoplasms primarily consisting of mature adipose tissue intertwined with myeloid tissue. They constitute a noteworthy portion, ranging from 6% to 16%, of adrenal incidentalomas, emerging as the second most frequent etiology following adrenal adenomas. These lesions can exhibit functional or nonfunctional characteristics, adding a layer of complexity to their clinical evaluation and management.</p>
        <p>This continuing education activity is designed to provide a comprehensive review of the assessment and treatment of adrenal myelolipomas. Additionally, it emphasizes the crucial role of the interprofessional healthcare team in recognizing and effectively managing patients with adrenal myelolipomas. By enhancing our collective understanding of these lesions and promoting interdisciplinary collaboration, we can optimize patient care, refine diagnostic strategies, and tailor treatment plans to individual patient needs.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between adrenal myelolipomas and other adrenal lesions through a standardized diagnostic approach, taking into account size, symptomatology, and risk factors to guide appropriate management decisions.</p></list-item><list-item><p>Screen patients with suspected adrenal myelolipomas for hormonal hypersecretion, employing relevant laboratory tests to identify potential endocrine abnormalities associated with these neoplasms.</p></list-item><list-item><p>Implement evidence-based guidelines for the surgical resection of adrenal myelolipomas, considering criteria such as neoplasm growth, size, symptomatic pain or mass effect, suspicion of malignancy, or hormonal hypersecretion.</p></list-item><list-item><p>Coordinate long-term follow-up care for patients with adrenal myelolipomas with primary care providers and other team members, including regular monitoring and timely intervention as necessary.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17236">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17236.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Adrenal myelolipomas are benign, nonfunctional adrenal neoplasms predominantly composed of mature adipose tissue and intermixed myeloid tissue. They comprise 6% to 16% of all adrenal incidentalomas and are the second most common cause of adrenal lesions after adrenal adenomas.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref></p>
        <p>The increased prevalence of adrenal myelolipomas is primarily due to markedly increased detection because of the wider accessibility and usage of computed tomography (CT) and magnetic resonance imaging (MRI) scans for unrelated reasons.&#x000a0;The pathogenesis of adrenal myelolipoma is believed to either be due to metaplastic change in the mesenchymal cells or to overstimulation by adrenocorticotrophic hormone (ACTH).<xref ref-type="bibr" rid="article-17236.r1">[1]</xref>&#x000a0;</p>
        <p>Clinically, they are usually small and asymptomatic but may present with abdominal pain, nausea, or vomiting. On CT scan, they appear as well-circumscribed, hypodense masses with an attenuation of 90 to 120 Hounsfield units (HU) or lower, depending on their fat content.<xref ref-type="bibr" rid="article-17236.r2">[2]</xref><xref ref-type="bibr" rid="article-17236.r3">[3]</xref><xref ref-type="bibr" rid="article-17236.r4">[4]</xref>&#x000a0;</p>
        <p>Myelolipomas are rarely encountered outside the adrenal glands and are termed extra-adrenal myelolipomas, most often found in the retroperitoneum, thorax, or pelvis.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref>&#x000a0;Surgical resection is indicated in cases of significant adrenal neoplasm growth (&#x0003e;1 cm in defined time period), size &#x0003e;7cm due to chance of rupture and bleeding, symptomatic pain or mass effect, suspicion of malignancy, or hormonal hypersecretion.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r5">[5]</xref></p>
      </sec>
      <sec id="article-17236.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The pathogenesis of adrenal myelolipomas is not definitively known, but many studies show a relation to ACTH stimulation. One hypothesis suggests that stimuli such as necrosis or inflammation could lead to the metaplasia of the reticuloendothelial cells, which could lead to the development of adrenal myelolipomas. The increased lesion incidence in the advanced years of life supports this hypothesis.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r6">[6]</xref></p>
        <p>Another theory is that embryological origins may contribute to myelolipoma development. In fetal circulation, until the bone marrow is fully mature, adrenal tissue is capable of hematopoiesis, and this is also present in adults with chronic anemia or hematologic disorders, such as thalassemias, hereditary spherocytosis, or sickle-cell anemia.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref> This finding is also supported by reports of large doses of erythropoietin-stimulating agents causing bilateral adrenal myelolipomas.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
        <p>Lastly, in an important historical study, Seyle and Stone noted that injection of crude anterior pituitary extract in rats leads to the transformation of the adrenal cortex into bone marrow-like tissue. In addition, the administration of "testoid components" in rats caused the formation of pure adipose tissue, and the administration of corticotrophic anterior pituitary extracts intensified this effect.<xref ref-type="bibr" rid="article-17236.r8">[8]</xref> Therefore, it was hypothesized that excess ACTH could be responsible for the pathogenesis of adrenal myelolipomas. This theory is supported by the increased incidence of adrenal myelolipomas in congenital adrenal hyperplasia (CAH), where the levels of ACTH are usually significantly elevated.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r6">[6]</xref>&#x000a0;Patients with genetically proven CAH may have up to a 36% incidence of adrenal myelolipomas. These lesions were also more likely to be bilateral and larger at diagnosis.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref>&#x000a0;This finding is not generally seen in primary adrenal insufficiency (Addison's disease), which is also associated with high levels of ACTH, likely due to insufficient activity of functional adrenal tissue.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
        <p>Adrenal myelolipomas have also been found to have a specific micro-RNA signature compared to other adrenocortical tumors. This may be important in the translation of messenger RNA signals to myelolipoma formation and may be an additional biomarker to evaluate.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
        <p>Adrenal myelolipoma is sometimes associated with conditions like Cushing disease, obesity, hyperlipidemia, hypertension, and diabetes, which can be considered adrenal stimulants. Other theories propose that a stressful lifestyle and an unbalanced diet may also play a role in the natural history of the neoplasm.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r6">[6]</xref></p>
      </sec>
      <sec id="article-17236.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>About 80% of all adrenal incidentalomas are nonfunctional, and over 90% are benign. Adrenal myelolipomas are the second most common adrenal lesions, comprising 6% to 16% of all adrenal incidentalomas.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r9">[9]</xref><xref ref-type="bibr" rid="article-17236.r10">[10]</xref>&#x000a0;The incidence is much higher in patients with CAH; however, the Endocrine Society does not recommend routine screening for adrenal tumors in these patients.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
        <p>Adrenal myelolipomas have an approximate autopsy prevalence of 0.08 to 0.2%.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref>&#x000a0;They are usually diagnosed in those aged 40 to 70 years, with a median age of diagnosis around 62 years.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r11">[11]</xref>&#x000a0;There is no gender predilection, but some studies suggest a slight preference for the right side.<xref ref-type="bibr" rid="article-17236.r11">[11]</xref></p>
      </sec>
      <sec id="article-17236.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Adrenal myelolipoma size can range from a few millimeters to greater than 10 cm. Those larger than 10 cm in size are called giant adrenal myelolipomas and are exceedingly rare.<xref ref-type="bibr" rid="article-17236.r12">[12]</xref><xref ref-type="bibr" rid="article-17236.r13">[13]</xref> The largest adrenal myelolipoma reported to date weighed 6 kg.<xref ref-type="bibr" rid="article-17236.r14">[14]</xref></p>
        <p>While generally considered nonfunctional, 10% to 15% of myelolipomas may be hormonally active. In addition, 6% of adrenal myelolipomas are associated with functioning or nonfunctioning adrenal adenomas. An endocrine workup is warranted if symptoms, signs, or lab abnormalities are present.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
      </sec>
      <sec id="article-17236.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On gross pathologic examination, a cut section of a myelolipoma has a variegated appearance consisting of bright yellow areas of fat, dark red areas of trilinear hematopoietic myeloid tissue, and areas with intermixed red and yellow components. The fat content varies but concentration is typically 25% to slightly more than 50%.&#x000a0;Areas of necrosis and calcification are common.<xref ref-type="bibr" rid="article-17236.r10">[10]</xref><xref ref-type="bibr" rid="article-17236.r15">[15]</xref>&#x000a0;</p>
        <p>On histopathologic examination, myelolipomas predominantly comprise fatty areas with interspersed hematopoietic tissue components and stem cells. These fatty elements and hematopoietic areas may be clearly separated or are often intermixed.<xref ref-type="bibr" rid="article-17236.r16">[16]</xref>&#x000a0;Tissue analysis will stain positive for an amalgamation of myeloid cells, erythroid cells, and megakaryocytes. In an isolated adrenal myelolipoma, a peripheral rim of normal adrenal cortical tissue can be commonly identified distinctly from the mass.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref><xref ref-type="bibr" rid="article-17236.r17">[17]</xref></p>
      </sec>
      <sec id="article-17236.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p><bold>Most Common Presenting Symptoms for Adrenal Myelolipomas</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal pain&#x02014;22.5%</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Flank pain&#x02014;13.9%</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal mass&#x02014;5.2%</p>
          </list-item>
        </list>
        <p>Dyspnea, back pain, fever, unexplained weight loss, and virilization can be the presenting symptoms of an adrenal myelolipoma. Patients with lesions&#x000a0;larger than 6 cm are more likely to present with bilateral disease and symptoms of mass effect, eg, abdominal, flank, or back pain and positional shortness of breath.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref>&#x000a0;Rupture of adrenal myelolipomas occurs primarily in those&#x000a0;larger than 8 cm.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
        <p>
<bold>Four Recognizable Clinicopathologic Patterns of Adrenal Myelolipomas</bold>
</p>
        <p>
<bold>Isolated Adrenal Myelolipoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myelolipomas occurring in an otherwise normal adrenal gland are the most common pattern of presentation. They are asymptomatic and are incidentally identified during the imaging investigation performed for some other reason.</p>
          </list-item>
        </list>
        <p>
<bold>Adrenal Myelolipoma with Acute Hemorrhage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Retroperitoneal hemorrhage is the most common complication occurring in adrenal myelolipoma. Isolated larger lesions (typically over 4 cm in size) and those predominantly composed of fat (greater than 50%) have a greater propensity for a hemorrhagic event. &#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Extra-Adrenal Myelolipoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myelolipomas outside the adrenal gland are most commonly found in the retroperitoneum, where presacral or perirenal locations are reported as the most common. Patients usually have no endocrine abnormalities or acute hemorrhage.</p>
          </list-item>
        </list>
        <p>
<bold>Adrenal Myelolipoma with Associated Adrenal Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with adrenal myelolipoma may have a separate endocrine disorder: hypercortisolism (Cushing syndrome), congenital adrenal hyperplasia, and primary hyperaldosteronism have been reported in patients with symptomatic adrenal myelolipomas.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17236.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>As these tumors are often nonfunctional, endocrinological tests are helpful to exclude functional adrenal masses, such as pheochromocytomas, from the differential diagnosis. The lesions usually present as low-attenuation fat interspersed with higher-attenuation myeloid components that appear cloudy, as strands, or as a nodule.</p>
        <p>Symptoms of a functional adrenal neoplasm would include the following examples of a potential hormonal excess:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Muscle weakness (especially proximal muscle)</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Uncontrollable severe hypertension</p>
          </list-item>
          <list-item>
            <p>Unexplained significant weight gain</p>
          </list-item>
          <list-item>
            <p>Unusual feminization</p>
          </list-item>
          <list-item>
            <p>Virilization</p>
          </list-item>
        </list>
        <p>Ultrasonography, CT scans, and MRI scans are all helpful in diagnosing adrenal masses such as myelolipomas, with CT scans being the most sensitive for identifying fat within the lesions. As mentioned earlier, adipose tissue makes up variable amounts of adrenal myelolipoma, readily detectable and measurable on CT scans.<xref ref-type="bibr" rid="article-17236.r10">[10]</xref><xref ref-type="bibr" rid="article-17236.r15">[15]</xref>&#x000a0;The myeloid component is usually contrast-enhancing.&#x000a0;</p>
        <p>If noncontrast CT demonstrates a lesion with a density of less than 10 Hounsfield units (HU) and endocrinological evaluation is negative, it has been suggested that a biopsy can be avoided. However, up to 12% of myelolipomas may be functional.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref>&#x000a0;The differential diagnosis of fat-containing, nonfunctional retroperitoneal masses includes retroperitoneal lipomas, liposarcomas, and renal angiomyolipomas.</p>
        <p>
<bold>Ultrasound</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myelolipomas have a typical appearance of a hyperechoic mass with intermixed hypoechoic regions. The variable proportions of the elements in the lesion mainly determine echogenicity. The areas of intermixed fatty and myeloid tissue are the most echogenic, whereas regions of pure fat may appear hypoechoic.<xref ref-type="bibr" rid="article-17236.r14">[14]</xref><xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Foci of calcification appear hyperechoic with acoustic shadowing. Myelolipomas have vague or no appreciable margins on ultrasound, as their sonic density is similar to the surrounding retroperitoneal fat.<xref ref-type="bibr" rid="article-17236.r14">[14]</xref><xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hemorrhage alters the sonographic picture, with hemorrhagic areas appearing hypoechoic compared with fat.<xref ref-type="bibr" rid="article-17236.r18">[18]</xref><xref ref-type="bibr" rid="article-17236.r19">[19]</xref><xref ref-type="bibr" rid="article-17236.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>CT Scan</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CT is the preferred imaging modality for diagnosing adrenal myelolipomas and&#x000a0;is the most sensitive imaging modality for detecting hemorrhage, which may be hyper or hypodense, depending on the age.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Large amounts of fat are frequently encountered with &#x0201c;smoky&#x0201d; or "variegated" areas of interspersed higher-attenuation&#x000a0;tissue. This denser tissue has attenuation values of 20&#x000a0;HU to&#x000a0;30 HU, inferring the presence of&#x000a0;both fat and myeloid elements.<xref ref-type="bibr" rid="article-17236.r14">[14]</xref><xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myelolipomas are usually relatively well-circumscribed; however, due to the presence of&#x000a0;abundant fat, they can be difficult to distinguish from surrounding retroperitoneal adipose tissue.<xref ref-type="bibr" rid="article-17236.r14">[14]</xref><xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Foci of punctate calcification may be seen in 25% to 30% of cases.</p>
          </list-item>
        </list>
        <p>
<bold>Magnetic Resonance Imaging</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The predominantly fatty areas in myelolipomas appear hyperintense on T1-weighted MRI scans and intermediate to hyperintense on T2-weighted scans. Admixed marrowlike elements have medium-intensity signals similar to that of the spleen.<xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fat-suppression techniques are best for demonstrating the fat in a myelolipoma with MRI. The presence of marrow-like elements or hemorrhage results in persistent areas of increased signal intensity on fat-suppressed MRI.<xref ref-type="bibr" rid="article-17236.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The imaging features of extra-adrenal myelolipomas are similar to those of adrenal myelolipoma and do not allow the distinction of an extra-adrenal myelolipoma from other fat-containing tumors.<xref ref-type="bibr" rid="article-17236.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>Due to the accurate ability of the different imaging modalities in diagnosing myelolipomas, biopsy is often unnecessary. Exceptions would be indeterminate imaging or features suggestive of adrenal carcinoma or liposarcoma.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref></p>
      </sec>
      <sec id="article-17236.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of adrenal myelolipomas should be determined based on the size of the lesion, the presence of any indications of possible malignancy, and the presence of symptoms. If there is any reasonable suspicion of a malignancy, the lesion should be treated surgically, but the treatment is usually conservative for most adrenal myelolipomas.<xref ref-type="bibr" rid="article-17236.r16">[16]</xref></p>
        <p>Small (&#x0003c;5 cm) nonfunctional lesions in asymptomatic patients are usually monitored with repeat imaging&#x000a0;6 months after the initial diagnosis and then yearly for 1 to&#x000a0;2 years.&#x000a0;Some guidelines recommend annual imaging and biochemical testing for up to five years because a small percentage (&#x0003c;10%) may develop late hormonal functionality.&#x000a0;</p>
        <p>Any significant enlargement on repeat imaging, defined as 1 cm or more, or the development of hormonal functionality indicates the need for surgical resection. Most nonfunctional adrenal masses remain stable in size and never develop any significant hormonal activity.<xref ref-type="bibr" rid="article-17236.r22">[22]</xref></p>
        <p>Symptomatic tumors, masses that are actively enlarging, hormonally active adrenal neoplasms, imaging that is suspicious for malignancy or local invasion, evidence of possible tumor rupture, active retroperitoneal bleeding, or myelolipomas larger than 6 cm should undergo&#x000a0;elective surgical excision.&#x000a0;The American Urological Association recommends surgical excision if the mass exceeds 5 cm.<xref ref-type="bibr" rid="article-17236.r5">[5]</xref><xref ref-type="bibr" rid="article-17236.r23">[23]</xref><xref ref-type="bibr" rid="article-17236.r24">[24]</xref><xref ref-type="bibr" rid="article-17236.r25">[25]</xref><xref ref-type="bibr" rid="article-17236.r26">[26]</xref>&#x000a0;</p>
        <p>This approach is based on the reported incidence of life-threatening emergencies caused by spontaneous rupture and hemorrhage within large lesions and long-term experience with a conservative approach to smaller, asymptomatic lesions. Also, adrenal masses larger than 6 cm have a 25% chance of an adrenal malignancy, a further indication for surgery.<xref ref-type="bibr" rid="article-17236.r27">[27]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Conventional or endoscopic access may be chosen according to the tumor size. Minimally invasive and endoscopic techniques are best utilized for&#x000a0;smaller-sized lesions, depending&#x000a0;on the operator's expertise.&#x000a0;Conventional surgery is usually preferred for larger masses.<xref ref-type="bibr" rid="article-17236.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An extraperitoneal approach is preferable as it leads to quicker recovery of the patient and fewer postoperative complications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The midline&#x000a0;approach is indicated for masses larger than 10 cm or in cases&#x000a0;with adhesions and infiltration of the surrounding structures.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Follow-up is mandatory regardless of which treatment method has been employed.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Summary of Indications for Surgical&#x000a0;Excision&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Active retroperitoneal bleeding</p>
          </list-item>
          <list-item>
            <p>Evidence of possible local invasion</p>
          </list-item>
          <list-item>
            <p>Hormonally active (functional) lesions</p>
          </list-item>
          <list-item>
            <p>Possible tumor rupture</p>
          </list-item>
          <list-item>
            <p>Suspicion of malignancy</p>
          </list-item>
          <list-item>
            <p>Symptomatic tumors (pain or discomfort)</p>
          </list-item>
          <list-item>
            <p>Tumors larger than 6 cm</p>
          </list-item>
          <list-item>
            <p>Tumors that are actively enlarging (1 cm or more)<xref ref-type="bibr" rid="article-17236.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Monitoring of Myelolipomas</bold>
</p>
        <p>Monitoring is appropriate for patients with myelolipomas that do not meet the criteria for surgical excision. These would typically be small (&#x0003c;4-5 cm), nonfunctional, asymptomatic adrenal lesions with significant fat content.</p>
        <p>Such monitoring would include the following American Urological Association Core Curriculum Recommendations:<xref ref-type="bibr" rid="article-17236.r22">[22]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Initial biochemical testing that is negative for hormonal activity.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Repeat imaging and biochemical testing 6 months after the initial diagnosis and then yearly for at least&#x000a0;1 to 2 years.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some guidelines recommend the annual imaging and biochemical testing continue for up to&#x000a0;5 years because a small percentage (&#x0003c;10%) may develop late hormonal functionality.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Most&#x000a0;lesions (75%-95%) remain stable in size over time, and less than 10% ever become hormonally active after initial negative testing.</p>
          </list-item>
        </list>
        <p>Other professional societies have different recommendations for monitoring adrenal myelolipomas.<xref ref-type="bibr" rid="article-17236.r29">[29]</xref><xref ref-type="bibr" rid="article-17236.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The 2016&#x000a0;European Society of Endocrinology and European Network for the Study of Adrenal Tumors guidelines do not recommend any follow-up imaging or biochemical testing if the initial workup shows a small lesion (&#x0003c;4 cm) with very low density (&#x0003c;10 HU on CT). If the lesion is greater than 4 cm or has indeterminate characteristics, then repeat imaging at&#x000a0;6 to 12 months is recommended.<xref ref-type="bibr" rid="article-17236.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The American College of Radiology guidelines are similar to the above except for a recommendation for a risk-stratified approach to further evaluation (PET-CT, biopsy, or surgery as appropriate) for adrenal masses less than 4 cm with indeterminate radiological characteristics.<xref ref-type="bibr" rid="article-17236.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17236.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Adrenal myelolipomas are typically nonfunctional; endocrinological testing can exclude functional adrenal masses. The remaining nonfunctional masses would include the following:</p>
        <p><bold>Benign adrenal adenoma:</bold> These are the most common adrenal incidentalomas. They are well-circumscribed, homogenous masses that have low attenuation in most cases. This low attenuation is due to the fatty tissue present in most adenomas. Lipid-poor adenomas can be observed with a greater attenuation value. While most adrenal adenomas are nonfunctional, some may be active endocrinologically.<xref ref-type="bibr" rid="article-17236.r31">[31]</xref><xref ref-type="bibr" rid="article-17236.r32">[32]</xref>&#x000a0;See our companion StatPearls reference article on "Adrenal Adenoma."<xref ref-type="bibr" rid="article-17236.r31">[31]</xref></p>
        <p><bold>Adrenal carcinoma:</bold> These are large, lobulated tumors with a heterogeneous appearance due to hemorrhage and necrosis. They have irregular margins and invade the surrounding structures&#x02014;inferior vena cava, kidney, and liver. They have an attenuation value greater than 10 HU and show increased uptake on the PET scan.<xref ref-type="bibr" rid="article-17236.r33">[33]</xref>&#x000a0;See our companion StatPearls reference article on "Adrenal Cancer."<xref ref-type="bibr" rid="article-17236.r33">[33]</xref></p>
        <p><bold>Retroperitoneal liposarcoma:</bold> This is a slow-growing tumor of the retroperitoneal region, composed of adipocytes, and radiologically appears similar to an adrenal myelolipoma.<xref ref-type="bibr" rid="article-17236.r32">[32]</xref><xref ref-type="bibr" rid="article-17236.r34">[34]</xref></p>
        <p><bold>Renal angiomyolipoma:</bold> Angiomyolipomas are tumors comprised of fat, blood vessels, and muscle cells. These are large, heterogeneous-appearing tumors that can invade through the renal capsule. The radiological appearance is similar to that of an adrenal myelolipoma with negative attenuation values; however, they arise from the kidney.<xref ref-type="bibr" rid="article-17236.r32">[32]</xref><xref ref-type="bibr" rid="article-17236.r35">[35]</xref>&#x000a0;See our companion StatPearls reference article on "Renal Angiomyolipoma."<xref ref-type="bibr" rid="article-17236.r35">[35]</xref></p>
        <p>In addition, any retroperitoneal mass can be included in the differential diagnosis, such as retroperitoneal lymphoma, lipoma, or metastatic disease. Given their significant vascularity, the adrenal glands are especially prone to metastatic disease.</p>
      </sec>
      <sec id="article-17236.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis of adrenal myelolipoma is generally good. One series followed 163 patients for a median of 7 years, and only 16% of patients showed a growth&#x000a0;&#x02265;1 cm.<xref ref-type="bibr" rid="article-17236.r7">[7]</xref>&#x000a0;Those who meet the criteria for surgery also do well, as there is no reported malignant potential.<xref ref-type="bibr" rid="article-17236.r5">[5]</xref>&#x000a0;Long-term survival with no recurrence of myelolipoma has been reported.<xref ref-type="bibr" rid="article-17236.r36">[36]</xref></p>
      </sec>
      <sec id="article-17236.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The&#x000a0;primary complications of adrenal myelolipomas include pain and mass effects. Hemorrhage and rupture are rare and occur when size exceeds 8 cm to 10 cm. If surgery is required, standard complications may accompany laparoscopic or open surgical procedures.&#x000a0;</p>
      </sec>
      <sec id="article-17236.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with adrenal myelolipomas should be educated about the disorder, options available for treatment, possible diagnostic procedures, suggested follow-up, and indications for surgical intervention. Patients can be assured that the condition is usually benign and can be treated conservatively.<xref ref-type="bibr" rid="article-17236.r1">[1]</xref><xref ref-type="bibr" rid="article-17236.r5">[5]</xref></p>
      </sec>
      <sec id="article-17236.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Functional tests for abnormal adrenal activity may include the following, as appropriate:<xref ref-type="bibr" rid="article-17236.r37">[37]</xref><xref ref-type="bibr" rid="article-17236.r38">[38]</xref><xref ref-type="bibr" rid="article-17236.r39">[39]</xref><xref ref-type="bibr" rid="article-17236.r40">[40]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Plasma ACTH, AM cortisol, aldosterone, androstenedione, 17-beta-estradiol, metanephrine, normetanephrine, 1 mg overnight dexamethasone suppression test, DHEAS, potassium, 17-OH-progesterone, renin, and testosterone (total and free).
<list list-type="bullet"><list-item><p>Sex hormone testing is warranted in feminization, virilization, suspected adrenal carcinoma, or the evaluation of adrenal masses &#x0003e; 4 cm.</p></list-item><list-item><p>Adrenal vein sampling may be needed in selected cases.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A 24-hour urine test for aldosterone, catecholamines, free cortisol, metanephrine, and&#x000a0;vanillylmandelic&#x000a0;acid.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17236.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with adrenal myelolipoma requires a collaborative effort among healthcare professionals, including physicians, advanced practice practitioners, nurses, pharmacists, and others. First and foremost, healthcare providers must possess the necessary clinical skills and expertise&#x000a0;when diagnosing, evaluating, and treating this condition. This includes proficiency in interpreting radiological findings, recognizing potential complications, and understanding the nuances of managing functional and nonfunctional myelolipomas. Urology or general surgery may require consultation depending on the size and location of the myeloplipoma.&#x000a0;Moreover, a strategic approach involving evidence-based guidelines and individualized care plans tailored to each patient's unique circumstances is vital.</p>
        <p>Ethical considerations come into play when determining treatment options and respecting patient autonomy in decision-making. Responsibilities within the interprofessional team should be clearly defined, with each member contributing their specialized knowledge and skills to optimize patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Lastly, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by adrenal myelolipoma.</p>
      </sec>
      <sec id="article-17236.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17236&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17236">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/adrenal-myelolipoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17236">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17236/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17236">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17236.s17">
        <fig id="article-17236.image.f1" position="float" orientation="portrait">
          <caption>
            <p>A large adrenal myelolipoma with predominantly fatty and intermixed intermediately attenuating components seen on CT Contributed by Jinnah Hospital; Lahore, Pakistan</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG-20170216-WA0015" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17236.s18">
        <title>References</title>
        <ref id="article-17236.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Decmann</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Perge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>T&#x000f3;th</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Igaz</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipoma: a comprehensive review.</article-title>
            <source>Endocrine</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-15</page-range>
            <pub-id pub-id-type="pmid">29164520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>CT and MRI of adrenal gland pathologies.</article-title>
            <source>Quant Imaging Med Surg</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>853</fpage>
            <page-range>853-875</page-range>
            <pub-id pub-id-type="pmid">30306064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujishita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kouda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kajiwara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanematsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oshiro</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A rare case of gradual enlargement of a multifocal myelolipoma of the posterior mediastinum for 12 years after surgical resection of an adrenal myelolipoma.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2018</year>
            <volume>51</volume>
            <fpage>400</fpage>
            <page-range>400-403</page-range>
            <pub-id pub-id-type="pmid">30273907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadood</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>DSA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>A rare case of co-existing adrenal and pelvic myelolipomas.</article-title>
            <source>Radiol Case Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>999</fpage>
            <page-range>999-1002</page-range>
            <pub-id pub-id-type="pmid">30116462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steka</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Renzulli</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hauswirth</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vrugt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Renzulli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipoma: Defining the role of surgery. A case report.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>98</volume>
            <fpage>107527</fpage>
            <pub-id pub-id-type="pmid">36030765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>An Unusual Cause of Cushing's Syndrome and Virilization.</article-title>
            <source>Gastroenterology</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>149</volume>
            <issue>4</issue>
            <fpage>e5</fpage>
            <page-range>e5-6</page-range>
            <pub-id pub-id-type="pmid">26302184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calissendorff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juhlin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Falhammar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipomas.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>767</fpage>
            <page-range>767-775</page-range>
            <pub-id pub-id-type="pmid">34450092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SELYE</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>STONE</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hormonally induced transformation of adrenal into myeloid tissue.</article-title>
            <source>Am J Pathol</source>
            <year>1950</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-33</page-range>
            <pub-id pub-id-type="pmid">15406252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wani</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kosar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rawa</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Qayum</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Giant adrenal myelolipoma: Incidentaloma with a rare incidental association.</article-title>
            <source>Urol Ann</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>130</fpage>
            <page-range>130-3</page-range>
            <pub-id pub-id-type="pmid">20981204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipoma: To operate or not? A case report and review of the literature.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2014</year>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>494</fpage>
            <page-range>494-6</page-range>
            <pub-id pub-id-type="pmid">24995663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Lipomatous tumours in adrenal gland: WHO updates and clinical implications.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>R65</fpage>
            <page-range>R65-R79</page-range>
            <pub-id pub-id-type="pmid">28143811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvarez</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Samreen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beegle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben-David</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Giant adrenal myelolipoma.</article-title>
            <source>J Gastrointest Surg</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>1716</fpage>
            <page-range>1716-8</page-range>
            <pub-id pub-id-type="pmid">24889790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandes</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kandalkar</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Giant adrenal myelolipoma.</article-title>
            <source>Indian J Pathol Microbiol</source>
            <year>2010</year>
            <season>Apr-Jun</season>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>325</fpage>
            <page-range>325-6</page-range>
            <pub-id pub-id-type="pmid">20551546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nabi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rafiq</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Authoy</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Sofi</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Incidental detection of adrenal myelolipoma: a case report and review of literature.</article-title>
            <source>Case Rep Urol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>789481</fpage>
            <pub-id pub-id-type="pmid">23509660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vajtai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Korngold</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>FV</given-names>
              </name>
            </person-group>
            <article-title>Suprarenal retroperitoneal liposarcoma with intracaval tumor thrombus: an imaging mimic of adrenocortical carcinoma.</article-title>
            <source>Clin Imaging</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-7</page-range>
            <pub-id pub-id-type="pmid">24075490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>The natural history and treatment of adrenal myelolipoma.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>157</volume>
            <issue>4</issue>
            <fpage>1213</fpage>
            <page-range>1213-6</page-range>
            <pub-id pub-id-type="pmid">9120904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Littrell</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Broski</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Extra-adrenal myelolipoma and extramedullary hematopoiesis: Imaging features of two similar benign fat-containing presacral masses that may mimic liposarcoma.</article-title>
            <source>Eur J Radiol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>93</volume>
            <fpage>185</fpage>
            <page-range>185-194</page-range>
            <pub-id pub-id-type="pmid">28668414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bracci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Santis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Del Gaudio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faugno</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zerunian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guido</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Polici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Polidori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pucciarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matarazzo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Laghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Lesions: A Review of Imaging.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2022</year>
            <month>Sep</month>
            <day>08</day>
            <volume>12</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">36140572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Keshavamurthy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pucar</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Adrenal Hemangioma Definite Diagnosis on CT, MRI, and FDG PET in a Patient With Primary Lung Cancer.</article-title>
            <source>Clin Nucl Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>e192</fpage>
            <page-range>e192-e194</page-range>
            <pub-id pub-id-type="pmid">29561525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Obasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Corwin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Fananapazir</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The radiographically diagnosed adrenal myelolipoma: what do we really know?</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-294</page-range>
            <pub-id pub-id-type="pmid">28866749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>d'Amuri</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Maestroni</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pagnini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Melani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ziglioli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Negrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cappabianca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reginelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barile</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Filippo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging of adrenal gland: state of the art.</article-title>
            <source>Gland Surg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>Suppl 3</issue>
            <fpage>S223</fpage>
            <page-range>S223-S232</page-range>
            <pub-id pub-id-type="pmid">31559189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nassiri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhanvadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Duddalwar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Discrepancies in the Recommended Management of Adrenal Incidentalomas by Various Guidelines.</article-title>
            <source>J Urol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>205</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-59</page-range>
            <pub-id pub-id-type="pmid">32856984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Thota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipoma: Controversies in its management.</article-title>
            <source>Indian J Urol</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-101</page-range>
            <pub-id pub-id-type="pmid">25878407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olivier</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Carballido</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>[Myelolipoma of the adrenal gland: preoperative diagnostic approach].</article-title>
            <source>Actas Urol Esp</source>
            <year>1989</year>
            <season>May-Jun</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-60</page-range>
            <pub-id pub-id-type="pmid">2669447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baisakh</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Chattoraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adrenal myelolipoma: A rare lesion of adrenal gland.</article-title>
            <source>Indian J Cancer</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>597</fpage>
            <page-range>597-8</page-range>
            <pub-id pub-id-type="pmid">26960489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Case report: Adrenal myelolipoma resected by laparoscopic surgery.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>1058211</fpage>
            <pub-id pub-id-type="pmid">36544699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeiger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Hamrahian</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Angelos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elaraj</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kharlip</surname>
                <given-names>J</given-names>
              </name>
              <collab>American Association of Clinical Endocrinologists</collab>
              <collab>American Association of Endocrine Surgeons</collab>
            </person-group>
            <article-title>American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations.</article-title>
            <source>Endocr Pract</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>450</fpage>
            <page-range>450-3</page-range>
            <pub-id pub-id-type="pmid">19632968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Scholten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chomsky-Higgins</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nwaogu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Seib</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors Associated With Perioperative Complications and Prolonged Length of Stay After Laparoscopic Adrenalectomy.</article-title>
            <source>JAMA Surg</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>153</volume>
            <issue>11</issue>
            <fpage>1036</fpage>
            <page-range>1036-1041</page-range>
            <pub-id pub-id-type="pmid">30090934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fassnacht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arlt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dralle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Newell-Price</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahdev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabarin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terzolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsagarakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>175</volume>
            <issue>2</issue>
            <fpage>G1</fpage>
            <page-range>G1-G34</page-range>
            <pub-id pub-id-type="pmid">27390021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayo-Smith</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Israel</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mazzaglia</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Berland</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Pandharipande</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Management of Incidental Adrenal Masses:&#x000a0;A White Paper of the ACR Incidental Findings Committee.</article-title>
            <source>J Am Coll Radiol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>1038</fpage>
            <page-range>1038-1044</page-range>
            <pub-id pub-id-type="pmid">28651988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahmood</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Loughner</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Adrenal Adenoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30969728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dogra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Juhlin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Calissendorff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falhammar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Rare benign adrenal lesions.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2023</year>
            <month>Apr</month>
            <day>05</day>
            <volume>188</volume>
            <issue>4</issue>
            <fpage>407</fpage>
            <page-range>407-420</page-range>
            <pub-id pub-id-type="pmid">36943310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Torti</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Adrenal Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">31536189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siew</surname>
                <given-names>CCH</given-names>
              </name>
              <name>
                <surname>Apte</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Baia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gyorki</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Houdt</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Retroperitoneal and Mesenteric Liposarcomas.</article-title>
            <source>Surg Oncol Clin N Am</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-417</page-range>
            <pub-id pub-id-type="pmid">35715141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shamam</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Renal Angiomyolipoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">36256751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannidis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Papaemmanouil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chatzopoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paraskevas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Konstantara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotronis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kakoutis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Makrantonakis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Giant bilateral symptomatic adrenal myelolipomas associated with congenital adrenal hyperplasia.</article-title>
            <source>Pathol Oncol Res</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>775</fpage>
            <page-range>775-8</page-range>
            <pub-id pub-id-type="pmid">21222246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Pheochromocytoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">36944004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chaudhry</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Cushing Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29261900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Huecker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bhutta</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Dominique</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <chapter-title>Adrenal Insufficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28722862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17236.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dutt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wehrle</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Adrenal Gland</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30725945</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
